‘U.S. FDA Declines To Approve Regeneron High-dose Eylea’
- Market Screener Citing Reuters
https://www.marketscreener.com/quote/stock/REGENERON-PHARMACEUTICALS-10649/news/US-FDA-declines-to-approve-Regeneron-high-dose-Eylea-44205395/
FDA Approves Rystiggo: The Only Treatment for Two Most Common Subtypes of Generalized Myasthenia Gravis in Adults
The FDA approved UCB SA's (OTC: UCBJF) (OTC: UCBJY) Rystiggo (rozanolixizumab-noli) for generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AchR) or anti-muscle-specific tyrosine
INVO Receives FDA Clearance For Expanded Use Of The INVOcell Device
INVOcell now cleared for 5-day incubation period
Supporting data reflects improved patient outcomes, similar to IVF
Inozyme Pharma Announces Dosing Of First Infant With ENPP1 Deficiency In A Phase 1b Trial Of INZ-701
Inozyme Pharma, Inc. (NASDAQ:INZY), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of pathologic mineralization and intimal proliferation, today
Ocuphire Presents APX3330 ZETA-1 Clinical Data In Late-Breaker Session At The American Diabetes Association’s Annual Conference
Ocuphire Pharma, Inc. (NASDAQ:OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing small-molecule therapies for the treatment of retinal and refractive eye
Regulus Therapeutics Announces First Patient Dosed In Second Cohort Of Phase 1b Multiple-Ascending Dose Clinical Trial Of RGLS8429 For The Treatment Of Autosomal Dominant Polycystic Kidney Disease
Regulus Therapeutics Inc. (NASDAQ:RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today announced
Second Most Prevalent Bacterial Sexually Transmitted Infection: GSK’s Gonorrhea Vaccine Secures FDA Track
The FDA has granted Fast Track designation to GSK plc's (NYSE:
ReShape Lifesciences Submits FDA PMA Supplement Application For The Next-Generation Lap-Band 2.0
ReShape Lifesciences® (NASDAQ:RSLS), the premier physician-led weight loss and metabolic health solutions company, today announced the submission of a Premarket Approval (PMA) supplement application to the
Edgewise Therapeutics Announces 12-Month Topline Results From The ARCH Open Label Study Of EDG-5506 In Adults With Becker Muscular Dystrophy
– Sustained positive trend in North Star Ambulatory Assessment (NSAA) scores relative to BMD natural history –
– Significant decreases in levels of serum creatine kinase (CK) and fast skeletal muscle
Teleflex Recalls Certain Arrow Peripheral Catheter System Citing Risk Of Separation, Leakage
Teleflex Incorporated (NYSE: TFX) and its subsidiary Arrow International are recalling the ARROW Endurance Extended Dwell Peripheral Catheter System after reports of catheter separation or leakage.
The FDA has identified this as a Class I recall, the most serious type of recall.